MENLO PARK, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today reported financial results for the quarter ended March 31, 2017 and provided an update on its clinical development programs.
“We are off to a great start in 2017, including the successful completion of our third Phase 3 clinical trial for CIMZIA, a pre-NDA meeting with the FDA for glycopyrronium tosylate and the closing of a successful follow-on offering,” said Tom Wiggans, chairman and chief executive officer of Dermira. “As we prepare for the remainder of the year, we anticipate UCB submitting marketing applications for CIMZIA for the treatment of chronic plaque psoriasis in the United States, Europe and Canada in the third quarter and we expect to submit a new drug application for glycopyrronium tosylate for the treatment of axillary hyperhidrosis in the second half of this year. We also continue to work on expanding our product portfolio and have made progress on building our commercial operations, which we plan to provide an update on later in the year.”
“We are off to a great start in 2017, including the successful completion of our third Phase 3 clinical trial for CIMZIA, a pre-NDA meeting with the FDA for glycopyrronium tosylate and the closing of a successful follow-on offering,” said Tom Wiggans, chairman and chief executive officer of Dermira. “As we prepare for the remainder of the year, we anticipate UCB submitting marketing applications for CIMZIA for the treatment of chronic plaque psoriasis in the United States, Europe and Canada in the third quarter and we expect to submit a new drug application for glycopyrronium tosylate for the treatment of axillary hyperhidrosis in the second half of this year. We also continue to work on expanding our product portfolio and have made progress on building our commercial operations, which we plan to provide an update on later in the year.”
